Jump to the top of the page

Showing 730 – 740 of 1302 results

  • Four William Blair Advisors Make Financial Planning Top 40 Regional Advisors Under 40 List

    David Brown, David Dreifuss, Andrew Feichter, and Andrew Sims were named to Financial Planning magazine’s Top 40 Regional Advisors Under 40 list released on February 2.

  • Corporate Equality Index

    William Blair received a perfect score of 100% on the 2021 Corporate Equality Index, a national benchmark that measures corporate policies and practices related to LGBTQ workplace equality.

  • Solange Velazquez Most Influential Women Award

    Solange-Marie Velazquez, a managing director in William Blair’s technology investment banking group, was named to Mergers & Acquisitions’ 2023 Most Influential Women in Mid-Market M&A list published February 27.

  • An Update on the Housing Market

    In this week’s Economics Weekly, we are once again taking a snapshot of the current housing situation, with the conclusion that a continued moderate recovery in housing is still the base-case scenario.

  • Contino Has Agreed to be Acquired by Cognizant

    William Blair acted as exclusive financial advisor to Contino, majority-owned by Columbia Capital, in connection with its pending acquisition by Cognizant.

  • The Employment Situation

    In this Economics Weekly we parse this week’s reports and what they are telling us about strength in the labor market and the economy more broadly.

  • And Now for the Inventory Correction

    In this Economics Weekly, we examine the current inventory situation—with supply chains now clearing but demand slowing, companies are getting a better sense of stock levels and of how much is too much.

  • COVID19s Impact on Specialty Distribution

    The COVID-19 pandemic has pressured supply chains across industries, but the net impact has varied significantly depending on the end-market.

  • Digitalization Driving Decarbonization

    Everything around us is getting smarter—buildings, cars, cities. And ESG factors are accelerating this trend.

  • The Quarterly Rx 2024 US Biopharma Recap

    The William Blair biopharma team recaps key financing and strategic transaction activity from 2024, a year defined by resilience and recovery.